These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27501352)

  • 1. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial.
    Kulkarni S; Kirkiles-Smith NC; Deng YH; Formica RN; Moeckel G; Broecker V; Bow L; Tomlin R; Pober JS
    Am J Transplant; 2017 Mar; 17(3):682-691. PubMed ID: 27501352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
    Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
    Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
    Glotz D; Russ G; Rostaing L; Legendre C; Tufveson G; Chadban S; Grinyó J; Mamode N; Rigotti P; Couzi L; Büchler M; Sandrini S; Dain B; Garfield M; Ogawa M; Richard T; Marks WH;
    Am J Transplant; 2019 Oct; 19(10):2865-2875. PubMed ID: 31012541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
    Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
    Stegall MD; Diwan T; Raghavaiah S; Cornell LD; Burns J; Dean PG; Cosio FG; Gandhi MJ; Kremers W; Gloor JM
    Am J Transplant; 2011 Nov; 11(11):2405-13. PubMed ID: 21942930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.
    Schinstock CA; Bentall AJ; Smith BH; Cornell LD; Everly M; Gandhi MJ; Stegall MD
    Am J Transplant; 2019 Jun; 19(6):1671-1683. PubMed ID: 30412654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.
    Viglietti D; Gosset C; Loupy A; Deville L; Verine J; Zeevi A; Glotz D; Lefaucheur C
    Am J Transplant; 2016 May; 16(5):1596-603. PubMed ID: 26693703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.
    Jordan SC; Choi J; Aubert O; Haas M; Loupy A; Huang E; Peng A; Kim I; Louie S; Ammerman N; Najjar R; Puliyanda D; Vo A
    Am J Transplant; 2018 Dec; 18(12):2955-2964. PubMed ID: 29637714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
    Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
    Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
    Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
    Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.
    Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
    Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
    Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases.
    Tan EK; Bentall A; Dean PG; Shaheen MF; Stegall MD; Schinstock CA
    Transplantation; 2019 Nov; 103(11):2397-2404. PubMed ID: 30801549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
    Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
    Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.
    Luque S; Lúcia M; Melilli E; Lefaucheur C; Crespo M; Loupy A; Bernal-Casas D; Gomà M; Jarque M; Crespo E; Montero N; Manonelles A; Cruzado JM; Gil-Vernet S; Grinyó JM; Bestard O
    Am J Transplant; 2019 Feb; 19(2):368-380. PubMed ID: 30085394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
    Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
    Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients.
    Adebiyi OO; Gralla J; Klem P; Freed B; Davis S; Wiseman AC; Cooper JE
    Am J Transplant; 2016 Dec; 16(12):3458-3467. PubMed ID: 27140940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
    Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
    Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.